Cartesian Therapeutics, Inc. (RNAC) shares surged 23.56 percent, gaining $1.39 to $7.25 on Tuesday after the late clinical-stage biotechnology company announced a strategic licensing agreement with WestGene Biopharma to advance the development of novel in vivo CAR-T therapies for autoimmune diseases.
The stock is currently trading at $7.25, compared with its previous close of $5.86 on the Nasdaq. During the session, it opened at $7.01 and traded between $7.00 and $9.33. Trading volume reached 2.57 million shares, significantly above its average volume of 172,425 shares.
The partnership is designed to combine Cartesian's expertise in autoimmune cell therapies with WestGene's targeted lipid nanoparticle delivery platform, potentially accelerating the development of next-generation treatments. The companies plan to evaluate proof-of-concept in patients with myasthenia gravis, with the potential to expand into multiple autoimmune disease indications if clinical results are positive.
Cartesian Therapeutics shares have traded between $5.60 and $15.57 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.